EuroSIVA 2025: A Historic Gathering of Intravenous Anaesthesia Experts in Buenos Aires
For the first time since its foundation in 1998, EuroSIVA – the European Society for Intravenous Anaesthesia – will host its full-format event outside Europe. From May 15 to 17, 2025, Buenos Aires will welcome leading anaesthesiologists, researchers, and clinicians from around the world for a three-day conference fully dedicated to Total Intravenous Anaesthesia (TIVA). A Milestone in Anaesthesia Education EuroSIVA has been a key player in education and research in intravenous anaesthesia pharmacology. This year’s event at Palais Rouge in Buenos Aires marks an exciting expansion of its global reach. The conference will include keynote lectures, interactive workshops, and live clinical case discussions, focusing on TIVA, Target-Controlled Infusion (TCI), and advanced perioperative monitoring. This event is part of EuroSIVA on Tour, a new initiative bringing intravenous anaesthesia education beyond Europe. Other activities include EuroSIVA’s participation in ADAAC 2025 – the leading anaesthesia educational event in the Gulf Region. Programme Highlights The agenda will cover a wide range of topics
EuroSIVA Joins the Leading Anesthesia Educational Event in the Gulf Region: ADAAC 2025
EuroSIVA is proud to announce its participation in the Abu Dhabi Annual Anesthesia Congress (ADAAC), the premier educational event for anesthesiologists in the Gulf region, organized in conjunction with the Euro-Abu Dhabi Intensive Care Congress. For the first time in the Middle East, EuroSIVA will host an exclusive Total Intravenous Anesthesia (TIVA/TCI) Workshop on 14 September 2025 at Conrad Abu Dhabi Etihad Towers, UAE. The workshop agenda includes plenary lectures on pharmacokinetics, pharmacodynamics, EEG monitoring, and drug interactions, as well as focused sessions on PK/PD modeling, TCI in special populations (children, elderly, obese), and practical exercises with TCI pumps and TIVATrainer software. Participants will have the opportunity to learn from leading international experts in the field: Dr. Francisco A. Lobo (UAE) – EuroSIVA Chairman and Editor-in-Chief of Journal of Clinical Monitoring and Computing Dr. Siarhei Kastsiauchenka (UAE) – Anesthesiologist at Cleveland Clinic Abu Dhabi Dr. Frank Engbers (Netherlands) – EuroSIVA secretary and Developer of TIVATrainer and LabelSyringe Dr. Hugo Vereecke
Thank you to our Sponsors for supporting EUROSIVA Lisbon 2025!
We are pleased to express our deepest gratitude to Fresenius, Masimo, Neurowaves, and BD for their generous support of Lisboa 2025 – Make TIVA Simple Again, our upcoming postgraduate course on IV Anesthetic Pharmacology and Perioperative Monitoring. The event will take place on May 23–24, 2025, at the Main Auditorium, Edifício Egas Moniz, Faculdade de Medicina de Lisboa. This high-level academic gathering has been awarded 15 CME credits by the European Accreditation Council for Continuing Medical Education (EACCME), underscoring the educational value and relevance of the program. Thanks to our sponsors, we are able to bring together leading experts in intravenous anesthesia and perioperative care to share cutting-edge insights, foster interactive learning, and contribute to the continuous professional development of anesthesiologists and critical care providers. 📝 Registration is now open: http://eurosiva.eu/registration We look forward to welcoming you in Lisbon for two days of stimulating lectures, practical knowledge, and collaborative exchange. Once again, thank you to Fresenius, Masimo, Neurowaves, and BD
Eurosiva 2025: Highlights from the Scientific Programme
Join us in Lisbon, Portugal, for the EUROSIVA 2025 Postgraduate Course on IV Anaesthetic Pharmacology and Perioperative Monitoring, awarded 15 CME credits by the EACCME®. 📅 Dates: 23–24 May 2025 📍 Venue: Main Auditorium, Edificio Egas Moniz, Faculdade de Medicina de Lisboa 🧠 Highlights from the Scientific Programme: 🎤 Day 1 – Friday, May 23 Session 1 – Basics in TIVA Why to use TIVA – Francisco Lobo Pharmacokinetics – Johan Raeder Pharmacodynamics: My KeO is better than yours – Frank Engbers Allometric scaling – Hernan Boveri TCI and drug interactions – Gavin Kenny Optimizing TCI in clinical practice – Nick Sutcliffe Session 2 – Updates on IV Anaesthetic Drugs Lidocaine, Ketamine, Remimazolam, Dexmedetomidine with Frank Engbers, Luc Barvais, Nick Sutcliffe and Francisco Lobo Session 3 – Monitoring and Multimodal Strategies Multimodal anesthesia and sedation – Francisco Lobo Multimodal monitoring – Luc Barvais TivatrainerX workshop – Frank Engbers 🎤 Day 2 – Saturday, May 24 New applications: Patient Maintained Sedation
Eurosiva Lisbon 2025 Awarded 15 CMEs by EACCME®
We are pleased to announce that the Eurosiva Lisbon 2025 postgraduate course on IV Anesthetic Pharmacology and Perioperative Monitoring has been awarded 15 CME credits by the European Accreditation Council for Continuing Medical Education (EACCME®). This accreditation underscores the course’s high educational value for anesthesiologists looking to enhance their knowledge and skills in Total Intravenous Anesthesia (TIVA). By attending, participants will not only gain cutting-edge insights into IV anesthetic pharmacology but also earn valuable CME credits to advance their professional development. 📅Event Details: Dates: May 23-24, 2025 Location: Lisbon, Portugal Registration: http://eurosiva.eu/registration Additionally, this year’s Eurosiva Lisbon course takes place immediately before the ESAIC Euroanaesthesia Congress, making it an excellent opportunity to combine both educational experiences in one trip. Participants can deepen their TIVA expertise at Eurosiva and then continue their learning journey at one of the largest anesthesia congresses in the world.Register now and take advantage of this unique opportunity to expand your expertise, connect with international experts, and
Wintermeeting 2024: Hernan Boveri
Lost in LOC. Titrating to effect. What does it reveal? Dr. Hernán Boveri, Italian Hospital of Buenos Aires, Argentina. Saturday 20 January 9:00-9:30 Currently, propofol is the most widely used intravenous anesthetic drug capable of providing safe general anesthesia. Propofol can be administered using different techniques including target-controlled infusion (TCI).One of the greatest strengths of TCI technology lies in its ability to maintain the pharmacological condition once the predefined clinical effect has been achieved. TCI models were developed based on data from healthy volunteers and may not apply to all clinical situations, potentially resulting in under-dosing or overdosing both of which are adverse situations for patients. Individual variability in the pharmacokinetic parameters of anesthetics is a clinical challenge, as is pharmacodynamic variability. The large variation between patients in the concentration at the effect site that produces unconsciousness makes it difficult to establish the minimum concentration that provides effective sedation in a given patient. This would be of little importance if
Wintermeeting 2024 : Stefan Schraag
The different models implemented in TCI:how it happend and who is responsible Stefan Schraag Saturday 10:30-11:00 Who safeguards PK models? It is a tricky task for most to develop a pharmacokinetic model. It gets even more difficult to publish one without any typos. And then, once you have achieved that, what to do with it and how? This is one of the questions surrounding the governance of pharmacokinetic and pharmacodynamic research and scientific output when it informs medical device development and, ultimately, patient care. Since its inaugural incarnation in 1996, Target Controlled Infusion of propofol is such an example of a patient facing class 3 medical device supported by a pharmacokinetic model. Without going through the details of regulatory approval and post-market surveillance as demanded by the new Medical Device Regulations in Europe, I will discuss a few key questions that have been coming up over the last 25 years on TCI, its devices and model implementations. A great place
Wintermeeting 2024: Nick Sutcliffe
Why Total Intravenous Anaesthesia (TIVA) An overview on aspects of patient outcome, oncology, and the environment. Nick Sutcliffe Friday 19 January 8:30-9:00 Introduction The safety of surgery under anaesthesia has improved markedly over the last century. New drugs and improved equipment have resulted in more accurate dosing and reduced side effects. As mortality has improved, focus has shifted to also include non-lethal postoperative complications such as nausea, vomiting, pain, and cognitive dysfunction. Similarly, it is no longer sufficient to consider only immediate survival after surgery, but also longer-term issues such as cancer recurrence, quality of life and cognitive decline following surgery under anaesthesia. Propofol based TIVA has several potential advantages over volatile based anaesthesia (VBA), for both the patient and operating room staff, as well as environmental benefits. Evidence is accumulating to support the use of TIVA over VBA, in terms of improved patient outcomes, less toxicity in the local environment and less effect on the global environment relating to